Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Angeion on track to implant Model 2020 ICDs in U.S., Europe by year-end; Sentinel trials on hold.

This article was originally published in The Gray Sheet

Executive Summary

ANGEION MODEL 2020 ICD INITIAL IMPLANTS REMAIN ON SCHEDULE for December despite a suspension of Sentinel series implantable cardioverter defibrillator device implants announced by the company Nov. 12, Angeion President and CEO Whitney McFarlin reported during a same-day teleconference. Clinical development of the 46 cc 2020 ICD will be pursued in the U.S. and Europe, and investigational device exemption and CE Mark approvals are expected before year-end.
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT009114

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel